Ligand validation:7DY1

ATP: ADENOSINE-5'-TRIPHOSPHATE

ATP is a Ligand Of Interest in 7DY1 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
7DY1_ATP_A_602	90%	55%	0.096	0.979	0.73	0.99	-	2	0	0	100%	1
7DY1_ATP_C_602	86%	60%	0.1	0.968	0.7	0.84	-	1	0	0	100%	1
7DY1_ATP_D_602	85%	62%	0.099	0.966	0.71	0.75	-	1	2	0	100%	1
7DY1_ATP_E_602	85%	59%	0.108	0.973	0.85	0.72	-	-	0	0	100%	1
7DY1_ATP_E_601	84%	58%	0.106	0.969	0.73	0.86	-	1	1	0	100%	1
7DY1_ATP_B_602	84%	59%	0.11	0.973	0.68	0.89	-	1	0	0	100%	1
7DY1_ATP_F_602	84%	60%	0.098	0.96	0.65	0.86	-	1	1	0	100%	1
7DY1_ATP_C_601	84%	55%	0.104	0.966	0.71	1.01	1	1	1	0	100%	1
7DY1_ATP_B_601	83%	55%	0.098	0.958	0.62	1.09	-	2	0	0	100%	1
7DY1_ATP_D_601	83%	55%	0.106	0.965	0.74	0.99	-	2	0	0	100%	1
7DY1_ATP_A_601	82%	52%	0.116	0.971	0.72	1.11	-	1	0	0	100%	1
7DY1_ATP_F_601	80%	53%	0.11	0.96	0.7	1.11	-	4	4	0	100%	1
4O0M_ATP_A_802	75%	46%	0.1	0.934	0.94	1.13	-	2	0	0	100%	1
2PNN_ATP_A_374	100%	30%	0.027	0.995	1.34	1.43	4	5	2	0	100%	0.9774
5J1T_ATP_A_401	100%	31%	0.03	0.994	1.31	1.43	2	7	0	0	100%	1
1XDN_ATP_A_501	100%	45%	0.03	0.99	1	1.14	2	3	0	0	100%	1
3MHY_ATP_C_113	100%	53%	0.034	0.992	0.86	0.94	-	2	0	0	100%	1
4CBU_ATP_A_1369	100%	50%	0.045	0.997	0.68	1.25	-	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.